Data / Form D filings / Orchard Therapeutics plc
Orchard Therapeutics plc: Form D filings
Orchard Therapeutics plc, a biotechnology company in London, United Kingdom, filed 2 Form D notices with the SEC between 2021 and 2023. The latest, on March 23, 2023, reports $34 million sold of an offering with no set size to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 245 HAMMERSMITH ROAD, London, United Kingdom, W6 8P
- Phone
- 011-44-0-203-8088286
- Industry
- Biotechnology
- Entity type
- Other (Public limited company)
- Incorporated in
- United Kingdom
- Year incorporated
- 2018
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1748907
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 23, 2023 | New notice | Indefinite | $34,000,140 | 7 | Mar 10, 2023 | sec.gov | |
| Feb 24, 2021 | New notice | $149,999,996 | $149,999,996 | 24 | Feb 9, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James A. Geraghty | Director | |
| Joanne T. Beck | Director | |
| Bobby Gaspar | Executive Officer, Director | |
| Marc T. Dunoyer | Director | |
| Steven M. Altschuler | Director | |
| Frank E. Thomas | Executive Officer | |
| Alicia A. Secor | Director | |
| Charles A. Rowland, Jr. | Director | |
| John T. Curnutte | Director |
Every Form D from the week of Mar 20, 2023 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Orchard Therapeutics plc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.